Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AXGN 
Axogen Inc (AXGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: AXGN (4-star) is a STRONG-BUY. BUY since 28 days. Profits (19.91%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.71
1 Year Target Price $24.71
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.17% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 746.32M USD | Price to earnings Ratio - | 1Y Target Price 24.71 |
Price to earnings Ratio - | 1Y Target Price 24.71 | ||
Volume (30-day avg) 7 | Beta 0.99 | 52 Weeks Range 9.22 - 21.00 | Updated Date 08/30/2025 |
52 Weeks Range 9.22 - 21.00 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.06 | Actual 0.12 |
Profitability
Profit Margin -2.29% | Operating Margin (TTM) 2.95% |
Management Effectiveness
Return on Assets (TTM) 0.54% | Return on Equity (TTM) -4.48% |
Valuation
Trailing PE - | Forward PE 67.11 | Enterprise Value 780908944 | Price to Sales(TTM) 3.67 |
Enterprise Value 780908944 | Price to Sales(TTM) 3.67 | ||
Enterprise Value to Revenue 3.84 | Enterprise Value to EBITDA 72.04 | Shares Outstanding 46012600 | Shares Floating 45242324 |
Shares Outstanding 46012600 | Shares Floating 45242324 | ||
Percent Insiders 4.79 | Percent Institutions 87.52 |
Upturn AI SWOT
Axogen Inc
Company Overview
History and Background
Axogen Inc. was founded in 2002. It is a regenerative medicine company focused on developing and marketing innovative solutions for peripheral nerve repair. Its initial focus was on porcine submucosa xenografts, later expanding into nerve allografts and other nerve repair technologies.
Core Business Areas
- Nerve Repair and Regeneration: Axogen develops, commercializes, and markets products for surgical repair of peripheral nerves, utilizing both allograft and xenograft technologies.
Leadership and Structure
Karen Zaderej is the current Chairman, CEO, and President. The company has a typical corporate structure with departments for research, development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Avance Nerve Graft: An off-the-shelf, processed human nerve allograft for bridging nerve gaps. Axogen has a significant market share in nerve allografts. Competitors include Integra LifeSciences and Stryker, though Avance is a leading brand.
- Axoguard Nerve Connector: A porcine submucosa extracellular matrix (ECM) coaptation aid. Competitors include Integra LifeSciences and Stryker in the nerve repair market.
- Axoguard Nerve Protector: A porcine submucosa ECM for protecting injured peripheral nerves and tendons. Competitors are companies with similar products in this tissue repair area.
- Avive Soft Tissue Membrane: A human amniotic membrane used for soft tissue repair.
Market Dynamics
Industry Overview
The peripheral nerve repair market is growing due to increasing incidence of traumatic injuries, surgical procedures, and awareness of nerve repair options. It involves biologics, nerve conduits, and coaptation aids.
Positioning
Axogen is a key player in the nerve repair market, particularly known for its Avance Nerve Graft. Its competitive advantage lies in its specialized focus and established allograft processing capabilities.
Total Addressable Market (TAM)
TAM estimated to be over $2 billion for peripheral nerve repair market. Axogen is positioned to capture a significant portion through expanded offerings and clinical studies.
Upturn SWOT Analysis
Strengths
- Specialized focus on peripheral nerve repair
- Established allograft processing capabilities
- Strong brand recognition for Avance Nerve Graft
- Proprietary technologies
Weaknesses
- Reliance on allograft availability
- Relatively high product costs
- Limited product diversification beyond nerve repair
- History of fluctuating profitability
Opportunities
- Expanding product portfolio to address unmet needs
- Increasing market penetration through sales and marketing
- Gaining regulatory approvals for new products
- Expanding geographically
Threats
- Competition from larger medical device companies
- Potential disruptions in allograft supply
- Pricing pressures from healthcare providers
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- INTEGRA
- STRYKER
Competitive Landscape
Axogen's focus on nerve repair gives it an edge. Integra and Stryker offer a broader range of surgical products, leading to different priorities. Axogen needs to defend its allograft market share while innovating.
Growth Trajectory and Initiatives
Historical Growth: Axogen has demonstrated revenue growth historically, driven by increased adoption of its products and expansion into new markets.
Future Projections: Analyst projections generally expect continued revenue growth, driven by factors such as aging population, increasing trauma incidents, and demand for biologics-based solutions.
Recent Initiatives: Recent initiatives include expanded sales force, product development efforts, and clinical studies to support product adoption.
Summary
Axogen is a specialized regenerative medicine company focused on nerve repair with a strong position in the allograft market. Its strength lies in its proprietary technology and focused approach, but relies heavily on allograft supply. Future growth depends on product innovation and market expansion, but faces competition from larger players and potential disruptions in allograft supply chains.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available data and estimates, which are subject to change. It is not financial advice. Market share data is estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axogen Inc
Exchange NASDAQ | Headquaters Alachua, FL, United States | ||
IPO Launch date 1990-03-27 | President, CEO & Director Mr. Michael D. Dale | ||
Sector Healthcare | Industry Medical Devices | Full time employees 451 | Website https://www.axogeninc.com |
Full time employees 451 | Website https://www.axogeninc.com | ||
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.